Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Epogen Amgen · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Epoetin Hospira | EXPERIMENTAL | Epoetin Hospira |
| Epogen (Amgen) | ACTIVE_COMPARATOR | Epogen (Amgen) |
| Name | Type | Description |
|---|---|---|
| Epoetin Hospira | BIOLOGICAL | Variable dose |
| Epogen Amgen | BIOLOGICAL | Variable dose |
Inclusion Criteria: 1. Patient is able to provide written informed consent after risks and benefits of the study have been explained prior to any study related activities 2. Hemodialysis patients with chronic renal failure and renal anemia currently on stable Epogen (Amgen) dose administered IV or ...
Epogen Amgen is a monoclonal antibody being studied for use in chronic renal failure, specifically in patients requiring hemodialysis and receiving epoetin maintenance treatment. It is being investigated for the management of anemia in this patient population.
Epogen Amgen is being developed by Pfizer, Inc., which trades under the ticker PFE. The drug is currently in Phase 3 clinical development for chronic renal failure.
Epogen Amgen is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 3 study has been completed to evaluate its effects in patients with chronic renal failure.
Epogen Amgen has one completed Phase 3 clinical trial, NCT01473420, titled "A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment." The trial enrolled 320 participants in the United States.
Epogen Amgen is being compared to Epoetin Hospira in a clinical trial. The study is designed to compare the effects of subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in patients with chronic renal failure requiring hemodialysis.